TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...
Vasculitis Expert Receives the Vaccine
Vasculitis Expert Receives the Vaccine Dr. Carol Langford, Director of the Cleveland Clinic Center for Vasculitis Care and Research, received her first dose of a Covid-19 vaccine on New Year’s Eve. Dr. Langford is recognized worldwide for her clinical care and research in the field of vasculitis. Dr. Langford studies…...